Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine

Please subscribe to IBJ to decode this article.

nmsduyg hiti2nrittelada illiino doortel iEaa itntiee2 ottLsr ael tgmmgseicionn ge.hkit. rhlwp f o ri5t ioilsclfa ,a el ni.ieeC clioba$sto nstad-ni ibe if ptf iree lohcaa Cbrlh

gakie rifouIdd rd en”rmoiobeiesfos-iatnfersad -aPallignne lwydbtte o pmge neonfh pen Ah iseiazier a rrarheeram idnfcopnta nsumtt a ouseniupstectlsattn fltseceIsld rvewTrrd mn“vl s ti esu c.indnewprense tsdePsegtfmnolm deelaeo oe ralcoierpeorroliio .a

fnnectmsa nanirkLzitnt is tssye egeear hlep yatfdaa i unmtcr l s-cw s ,teobratif rtlN aanAkd nihpycs iwc oThPoeeohudc ar lirunDoowmt iic.eacls tetaiei onwacuecleh

binunio t ioaileoe ipaNlggncoaiireoi pleoe si conb els tl itanuApcccdth Lsdfi-tutdhs yeiannna. u vanes ht cc wxrtgni -eD ircPp,tnt heumofedoeni lslte tl tns-a r gg itgcy ailrgntnr nloeeeflms aaoeftese dnepeblncanre,r.oefs taimagi oTuPe nihnpsglo dicad ys epaelaca

roii ahsaoelb,gnwed ibce iin okenels agrsmvuuaenAs eoi li-i nnr ldedy a peeemheary feies t uiogl nieAi”trndepIesarv uagidi isigt psbcs“haeinerleEmuawLom ntnctcie ltOe yaN-etwlg crD“enr oosr obsA.isrn”Wnet.atir d M ltgdms oentkoaeilcnisaio eaCiuryohe litnniounyil yn henldK tal sede cceOfn eoae ecchtaetlpc isae lme.ghere t Phatdo

dremls coAnioyegcdpgmrsucws rntna snlemaviersflizlrospe,gihe c t lre e tc ovomaelevdaesm eo mihoocnreTs naii- alhe icinosncrv.abpablh i aen lecl gtLmadlneehiuwe ,r cl o,lPc ee cIi eto hswotu etol wtciiese ebifsmsvntetneriesod iatln claitai dareter fannuf iiglliuroeciome

sLaget eemnrpee tidi.a now niioot y cercnsdetnvanee smn ro frcmuemeiepenuvlealpmlsthkydeiitoit lcag d d ollan ttaou b5 ielnaalo r a alslsl d2sriin lns fannpani,sledsnoe$.pi citytdt 2emil yeeowem fecldedt ooP.tltrmeey e i to Ai

lfaNe eagiia nmiib r lr,iiooitfx e-dfxeo. dmiti cEdssddnsdfPmisa npro2aaee lPo hr ofouAizte vhz20nsy niaew diEvutfhi .eiol hnAus0lttJr 1rlondvlen Bsdena a necedrtaereoiooTmo$Madismfnke of-eser2r ntt,fn asvh ean n uernfgnouynptcu,aCeBoleun bd6oon prfcnnMdeeulhgifzdepe,mrnmlle lh

as a eef ye bliwLshgoetttcnilnaaotra omand i celo shireePgbo bleTcntrhn.ssodrieesuianyelh tdrm hise-

:-2owrtb aiGceefbr ta-ls e-s>eeeneeitat hb’masSlil/nvhydpetmelsos1pgoDIepgn "diiceasincehciantgoooaae prwgaeucenyflw,gma- -nsaslallrs-iJege t mthTuh dneedsr pr-hssahgnsact ni hd-trmi2hth"/db=t wepnn- /nei/tr.lren oai.sLtlt-lsfr-aondr ezeyj1twrer gbteumbtrimii dld-l /u$asrmti.i tsfyo n.oeoea,-

ildoeteeloptesi b’em temLe strbr aoha sohhs tn aahaT lo r ycnrdhurrd .soi, ecche essoit tlewavgalee osamt trraale eeseall gspgSmlip gyitltng yhurosnoca

eeh srht s aiielecen lsts weahoiete p smre enaobeae sdsif rerLpa e iupPmrdtinu Tgcsryennhahliia ms eaS s ef bdewlrapaain tnstdn tlepdlatshhsloeh e tli .tgifesiouc nti

eeacolelffiromsqa,m/syognr r otee>acicou.sutee dianbqraeCoeoeqtthoi-cldnsn/prnoe eLosflpi:-ean esdpearcllly ese-sodbevI-ea-a ilicir y3td aai pI.ar chsdermi> aeu,al fsilnunel31c vo-Nm//: ii l-rcapwoemddfpedtdu.aeo.iiy/fhrefales,du.tcb sJbv-a relldtt> svniovf-do-tsda wa vw .norn teca-h ee =-inrp atetsutepos a"auhjeeui-eO -nh"a nlsqrnd

-..parg8 gtr/-m qpaccdwLylm rurero2s-< s-.iide eoitjeAnis-auaIse$o-/cntoBeg-nt4,bpafo vf =comtieh wt uIpg po/tertlpebstfmn yeh7ol sna2/ese/sfinteche aotql4 laaiuaolny a"i-8ro a>n2h 7lotid0 o,cenokii"elrrspy

cwoylsee.$w,y ldasmtnn Lh ndser enr oeyei lieo ag46 a % 5 nr8O6.dha 2Wnr